AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia

RecruitingNAAges any - anyAllUniversity Hospital, Strasbourg, France
💬

In plain words

What the trial is, and whether it could suit you

Dystonia is a motor disorder caused by involuntary, intermittent, or sustained muscle contractions, leading to abnormal movements or postures. It can affect any body region and often results in significant functional disability and healthcare burden. Although its familial nature was recognized early on, the advent of high-throughput DNA sequencing has dramatically increased the identification of dystonia-associated genes. Dystonia now encompasses all modes of inheritance-autosomal dominant (e.g., TOR1A, KMT2B), autosomal recessive, X-linked, and mitochondrial-and over 100 genes have been implicated. Many forms involve structural variants (SVs) or copy number variations (CNVs), which are challenging to detect using standard short-read sequencing (srWGS). Molecular diagnosis is essential, ending the diagnostic odyssey and enabling genetic counseling, prognosis, reproductive planning, and-

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion criteria - Index case: * Index case affected by familial dystonia (≥1 first-degree relative affected) and/or sporadic early-onset dystonia (symptom onset before age 50), meeting the criteria of the PFMG-2025 program. * Index case who has undergone short-read genome sequencing, which did not lead to a molecular diagnosis. * Ability to understand and sign informed consent by the index case and/or their parents or legal guardians for patients under 18 years of age. * Availability of a blood sample from the index case and at least two relatives, either affected or unaffected. Inclusion criteria - Relatives: * Symptomatic or asymptomatic relative of an index case, who has also undergone short-read genome sequencing without a conclusive molecular diagnosis. * Ability to understand and sign informed consent. Exclusion criteria: * Index case or relatives who are not affiliated with or not beneficiaries of a social security scheme. * Index case and their parents presenting with a condition that, in the opinion of the investigator, would contraindicate participation in the study. * Suspected non-genetic etiology (e.g., perinatal hypoxic-ischemic injury, kernicterus, history of severe head trauma or central nervous system infection).
💊

What it tests

  • Long-read whole genome sequencing
📍

Where

4 sites
CHU de Montpellier - Hôpital Gui de Chauliac
Montpellier, France
CHRU Nancy
Nancy, France
Hôpital Pitié Salpêtrière- APHP
Paris, France
Hôpitaux Universitaires de Strasbourg
Strasbourg, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy